{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:09:42Z","timestamp":1769717382936,"version":"3.49.0"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"project FOCUS: Training and Guidance for UMFST Researchers in Health","award":["SMIS 350717"],"award-info":[{"award-number":["SMIS 350717"]}]},{"name":"European Union under the Health Programme of the Ministry of Investments and European Projects","award":["PS\/688\/PS_P3\/OP4\/ESO4.7\/PS_P3_ESO4.7_A6"],"award-info":[{"award-number":["PS\/688\/PS_P3\/OP4\/ESO4.7\/PS_P3_ESO4.7_A6"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Background: Environmental factors are known to influence the clinical presentation of patients with multiple sclerosis. This study aims to compare the demographic and clinical characteristics of multiple sclerosis patients treated at two diverse geographical settings. Methods: A cross-sectional, observational cohort study was conducted in two MS centers: the Danish Multiple Sclerosis Center (DMSC) in Copenhagen, Denmark and the Regional MS Center in T\u00e2rgu Mure\u0219, Romania. We compared patients\u2019 demographic and clinical characteristics between MS centers, including sex distribution, current age, MS onset age, latest EDSS scores, symptomatology at disease onset, MS phenotype and type of ongoing DMT. Results: In both cohorts, sex distribution was similar, with females constituting 69.2% in DMSC, and 65.7% in T\u00e2rgu Mure\u0219. Pyramidal symptoms at MS onset were predominant among Targu Mures patients (32.7%), while sensory symptoms were more frequent among DMSC patients (33%). Progressive forms of MS were more prevalent in T\u00e2rgu Mure\u0219 (22.6%) compared to DMSC (9.9%). High-efficacy DMTs were on use by 58.3% patients in DMSC and only by 29.4% patients in T\u00e2rgu Mure\u0219, who were mostly on low-efficacy DMTs (54.4% vs. 12.4% in DMSC). Conclusions: The study highlights both shared and distinct characteristics of MS patients treated in these two centers. These findings underscore the importance of regional considerations in the management and treatment of MS.<\/jats:p>","DOI":"10.3390\/neurolint18020025","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:12:01Z","timestamp":1769677921000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Clinical and Demographic Profiles of Multiple Sclerosis Patients in Two Regional Centers in Denmark and Romania"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-5864","authenticated-orcid":false,"given":"Oana","family":"Vr\u00eenceanu","sequence":"first","affiliation":[{"name":"Doctoral School, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"B\u0103la\u0219a","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Department of Neurology, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania"},{"name":"Ist Neurology Clinical, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaranda","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Neurology, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540136 Targu Mures, Romania"},{"name":"Ist Neurology Clinical, Emergency Clinical County Hospital Targu Mures, 540136 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-3827","authenticated-orcid":false,"given":"Luigi","family":"Pontieri","sequence":"additional","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital\u2014Rigshospitalet, Glostrup, DK-2600 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-5222","authenticated-orcid":false,"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[{"name":"The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital\u2014Rigshospitalet, Glostrup, DK-2600 Copenhagen, Denmark"},{"name":"Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital\u2014Rigshospitalet, Glostrup, DK-2600 Copenhagen, Denmark"},{"name":"Institute for Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 33.5, Section A, DK-2200 Copenhagen N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref_1","unstructured":"(2025, November 25). The Multiple Sclerosis International Federation Atlas of MS, 3rd ed, September 2020. Available online: https:\/\/www.atlasofms.org."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Balasa, R., Barcutean, L., Mosora, O., and Manu, D. (2021). Reviewing the Significance of Blood\u2013Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168370"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, L.Y., Wang, W.F., Hui, S.Y., Yang, L., Liu, Y.X., and Li, H.J. (2025). Emerging epidemiological trends of multiple sclerosis among adults aged 20\u201354 years, 1990\u20132021, with projections to 2035: A systematic analysis for the global burden of disease study 2021. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1616245"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104845","DOI":"10.1016\/j.msard.2023.104845","article-title":"Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022","volume":"77","author":"Maddox","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rivera, V.M. (2026). Multiple Sclerosis: An Ethnically Diverse Disease with Worldwide Equity Challenges Accessing Care. Neurol. Int., 18.","DOI":"10.3390\/neurolint18010002"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1468-1331.2010.03003.x","article-title":"Genetic and environmental factors and the distribution of multiple sclerosis in Europe","volume":"17","author":"Handel","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00415-025-13248-0","article-title":"Environmental risk factors for multiple sclerosis: A comprehensive systematic review and meta-analysis","volume":"272","author":"Vitturi","year":"2025","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40520-024-02712-y","article-title":"Association of Mediterranean diet adherence with disease progression, quality of life and physical activity, sociodemographic and anthropometric parameters, and serum biomarkers in community-dwelling older adults with multiple sclerosis: A cross-sectional study","volume":"36","author":"Tryfonos","year":"2024","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106739","DOI":"10.1016\/j.msard.2025.106739","article-title":"Efficacy of the Mediterranean diet in the treatment of multiple sclerosis (RRMS): A systematic review and meta-analysis","volume":"104","author":"Kong","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20250371","DOI":"10.1515\/tnsci-2025-0371","article-title":"From prevention to management: Exploring the impact of diet on multiple sclerosis","volume":"16","author":"Koukach","year":"2025","journal-title":"Transl. Neurosci."},{"key":"ref_12","first-page":"20552173251326173","article-title":"Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria-a nationwide population-based registry study over five decades","volume":"11","author":"Maunula","year":"2025","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Makarevi\u010dius, G., Kizlaitien\u0117, R., Kaubrys, G., and Giedraitien\u0117, N. (2025). Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: A single center, retrospective, observational study. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1635618"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review","volume":"80","author":"Cagol","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_15","unstructured":"World Health Organization (2020). Atlas: Multiple Sclerosis Resources in the World."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1177\/13524585221110582","article-title":"Changes in prognosis of the Danish multiple sclerosis population over time","volume":"28","author":"Magyari","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5603\/pjnns.103955","article-title":"Epidemiology of multiple sclerosis: Global trends, regional differences, and clinical implications","volume":"59","author":"Kochanowicz","year":"2025","journal-title":"Neurol. I Neurochir. Pol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Barcutean, L., Maier, S., Bajko, Z., Stoian, A., Mosora, O., Sarmasan, E., Manescu, I.B., and Balasa, R. (2024). Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061813"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_23","unstructured":"R Core Team (R: A Language and Environment for Statistical Computing, 2019). R: A Language and Environment for Statistical Computing, v. 3.6.1."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections","volume":"15","author":"Khan","year":"2025","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31925\/farmacia.2020.1.10","article-title":"Interferon-\u03b2 1a, an immunomodulator in relapsing remitting multiple sclerosis patients. The effect on pro-inflammatory cytokines","volume":"68","author":"Maier","year":"2020","journal-title":"Farmacia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1191\/135248506ms1323oa","article-title":"Immunomodulatory treatment of multiple sclerosis in denmark: A prospective nationwide survey","volume":"12","author":"Sorensen","year":"2006","journal-title":"Mult. Scler."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40263-025-01164-w","article-title":"Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study","volume":"39","author":"Sharmin","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17562864251398472","DOI":"10.1177\/17562864251398472","article-title":"From diagnosis to treatment: Patterns in disease-modifying therapy initiation in multiple sclerosis","volume":"18","author":"Iaquinto","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Radu, C., Serban, D.E., and Chiriac, N.D. (2025). Delayed access to innovative medicines in Romania: A comprehensive analysis of the reimbursement processes (2015\u20132024). Front. Public. Health, 13.","DOI":"10.3389\/fpubh.2025.1592419"},{"key":"ref_33","first-page":"165","article-title":"Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis","volume":"97","author":"Gavoille","year":"2026","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: Time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e70058","DOI":"10.1111\/ene.70058","article-title":"Smoking and Obesity Interact to Adversely Affect Disease Progression and Cognitive Performance in Multiple Sclerosis","volume":"32","author":"Eva","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_36","first-page":"14","article-title":"Multiple sclerosis: 2024 update","volume":"6","author":"Klotz","year":"2025","journal-title":"Free Neuropathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/acn3.70131","article-title":"Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis","volume":"12","author":"Iaffaldano","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s41669-024-00501-x","article-title":"Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment","volume":"8","author":"Wasem","year":"2024","journal-title":"PharmacoEconomics-Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/13524585251347513","article-title":"Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data","volume":"31","author":"Affinito","year":"2025","journal-title":"Mult. Scler. J."},{"key":"ref_40","first-page":"20552173251378788","article-title":"The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: An exploratory study","volume":"11","author":"Klistorner","year":"2025","journal-title":"Mult. Scler. J. Exp. Transl. Clin."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/18\/2\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:26:36Z","timestamp":1769678796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/18\/2\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["neurolint18020025"],"URL":"https:\/\/doi.org\/10.3390\/neurolint18020025","relation":{},"ISSN":["2035-8377"],"issn-type":[{"value":"2035-8377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}